EA202091516A1 - Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) - Google Patents
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)Info
- Publication number
- EA202091516A1 EA202091516A1 EA202091516A EA202091516A EA202091516A1 EA 202091516 A1 EA202091516 A1 EA 202091516A1 EA 202091516 A EA202091516 A EA 202091516A EA 202091516 A EA202091516 A EA 202091516A EA 202091516 A1 EA202091516 A1 EA 202091516A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- immune response
- methods
- hbv
- virus
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение относится к векторам на основе модифицированного вируса осповакцины Анкара (MVA) и аденовирусным векторам, кодирующим антигены HBV. Изобретение также относится к способам усиления иммунного ответа у субъекта-человека путем использования MVA и аденовирусных векторов, кодирующих антигены HBV в прайм/буст режиме для усиления иммунного ответа у субъекта-человека.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762607439P | 2017-12-19 | 2017-12-19 | |
PCT/IB2018/060257 WO2019123250A1 (en) | 2017-12-19 | 2018-12-18 | Methods and compositions for inducing an immune response against hepatitis b virus (hbv) |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091516A1 true EA202091516A1 (ru) | 2020-11-03 |
Family
ID=66815022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091516A EA202091516A1 (ru) | 2017-12-19 | 2018-12-18 | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) |
Country Status (2)
Country | Link |
---|---|
US (2) | US11020476B2 (ru) |
EA (1) | EA202091516A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3332007A4 (en) | 2015-08-07 | 2019-07-17 | Arrowhead Pharmaceuticals, Inc. | RNA INTERFERENCE THERAPY FOR HEPATITIS B VIRUS INFECTION |
MX2018012376A (es) | 2016-04-13 | 2019-08-01 | Synthetic Genomics Inc | Sistemas de replicón de arterivirus recombinantes y usos de estos. |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
AU2019210189A1 (en) | 2018-01-19 | 2020-08-06 | Janssen Pharmaceuticals, Inc. | Induce and enhance immune responses using recombinant replicon systems |
CN117843811A (zh) | 2019-09-30 | 2024-04-09 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US4738927A (en) | 1982-03-31 | 1988-04-19 | Ajinomoto Co. Inc. | Gene coded for interleukin-2 polypeptide, recombinant DNA carrying the said gene, a living cell line possessing the recombinant DNA, and method for producing interleukin-2 using the said cell |
US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
EP0165942A1 (en) | 1983-12-23 | 1986-01-02 | Monash University | PRODUCTION OF HUMAN INTERFERON-$g(a) |
AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
PT92479A (pt) | 1988-12-01 | 1990-06-29 | Univ North Carolina | Processo de preparacao de genes recombinantes e suas proteinas de codificacao |
US5225337A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
US5780036A (en) * | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
JP3650110B2 (ja) | 1993-08-02 | 2005-05-18 | ザ スクリップス リサーチ インスティテュート | B型肝炎ウイルスに対する細胞毒性tリンパ球応答を誘発するためのペプチド |
SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
DE19712889A1 (de) | 1997-03-27 | 1998-10-01 | Bosch Gmbh Robert | Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
CN1198665C (zh) | 1997-04-03 | 2005-04-27 | 依莱克脱罗弗克脱联合股份有限公司 | 将药物和核酸导入骨骼肌的方法 |
US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
US6117660A (en) | 1997-06-10 | 2000-09-12 | Cytopulse Sciences, Inc. | Method and apparatus for treating materials with electrical fields having varying orientations |
BR9810369A (pt) | 1997-06-30 | 2000-09-05 | Rhone Poulenc Rorer Sa | Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação |
US5958060A (en) | 1998-01-02 | 1999-09-28 | General Electric Company | Method and apparatus for clock control and synchronization |
US6697669B2 (en) | 1998-07-13 | 2004-02-24 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
US20040213805A1 (en) | 1999-10-12 | 2004-10-28 | Verheije Monique Helene | Deletions in arterivirus replicons |
US6982087B2 (en) | 2000-09-07 | 2006-01-03 | The University Of North Carolina At Chapel Hill | Vectors derived from South African Arbovirus No. 86 |
US6538922B1 (en) | 2000-09-27 | 2003-03-25 | Sandisk Corporation | Writable tracking cells |
AU2002231639B2 (en) | 2000-11-23 | 2007-01-04 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
WO2002061113A2 (en) | 2001-02-01 | 2002-08-08 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
DE60126595D1 (de) | 2001-07-19 | 2007-03-29 | Ericsson Telefon Ab L M | Verfahren und Vorrichtung für die Lösung der Nummernübertragbarkeit am Ursprungsort |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
WO2004055161A2 (en) | 2002-12-12 | 2004-07-01 | The Board Of Regents Of The University Of Texas System | Large scale production of packaged alphavirus replicons |
CA2520768A1 (en) * | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
PT1651666E (pt) | 2003-07-11 | 2009-08-28 | Alphavax Inc | Vacinas de citomegalovírus à base de alfavírus |
US20050070700A1 (en) | 2003-09-30 | 2005-03-31 | Matthias Giese | Equine arteritis virus vaccine |
NZ585119A (en) | 2004-03-08 | 2011-08-26 | Ichor Medical Systems Inc | Medical injector with surrounding electrical field generating penetrating electrodes |
WO2007140522A1 (en) * | 2006-06-06 | 2007-12-13 | Melbourne Health | Detection and use of antiviral resistance mutations |
WO2008020656A1 (en) | 2006-08-14 | 2008-02-21 | Postech Foundation | A dna vaccine for curing chronic hepatitis b and a method of preparing same |
KR100841732B1 (ko) | 2006-08-14 | 2008-06-27 | 포항공과대학교 산학협력단 | 만성 b형 간염의 치료를 위한 dna 백신 및 그의 제조방법 |
US20120121650A1 (en) | 2006-08-18 | 2012-05-17 | Johnston Robert E | Chimeric Virus Vaccines |
PT2066399T (pt) | 2006-10-17 | 2019-01-11 | Inovio Pharmaceuticals Inc | Dispositivos de eletroporação e métodos de usar os mesmos para eletroporação de células em mamíferos |
US20090018031A1 (en) | 2006-12-07 | 2009-01-15 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways tools, and methods |
KR100836745B1 (ko) * | 2007-01-31 | 2008-06-10 | (주)두비엘 | Hbv 백신 및 그의 제조 방법 |
EP2183368B1 (en) | 2007-06-21 | 2016-08-10 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
WO2009056535A2 (en) | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
EP2461826A2 (en) | 2009-08-07 | 2012-06-13 | Transgene SA | Composition for treating hbv infection |
ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
PT2590676T (pt) | 2010-07-06 | 2016-11-04 | Glaxosmithkline Biologicals Sa | Partículas de transferência de tipo virião para moléculas de arn auto-replicante |
CA2822462A1 (en) | 2010-12-20 | 2012-06-28 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
EP3760227A1 (en) | 2011-02-11 | 2021-01-06 | The Trustees of the University of Pennsylvania | Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same |
ES2643389T3 (es) | 2011-02-12 | 2017-11-22 | Globeimmune, Inc. | Producto terapéutico basado en levadura para infección por hepatitis B crónica |
TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
WO2014170493A2 (en) | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
CA2915730A1 (en) | 2013-08-21 | 2015-02-26 | Karl-Josef Kallen | A combination rsv/influenza a vaccine |
WO2016020538A1 (en) | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
AU2015323944B2 (en) | 2014-10-01 | 2018-11-29 | Inovio Pharmaceuticals, Inc. | Vaccines having an antigen and interleukin-21 as an adjuvant |
US11559570B2 (en) | 2015-05-15 | 2023-01-24 | CureVac SE | Prime-boost regimens involving administration of at least one mRNA construct |
JP7048482B2 (ja) | 2015-08-03 | 2022-04-05 | アメリカ合衆国 | Brachyury欠失変異体、Brachyury欠失変異体をコードする非酵母ベクター、及びそれらの使用 |
EP3371316B1 (en) | 2015-11-04 | 2022-10-19 | Hookipa Biotech GmbH | Vaccines against hepatitis b virus |
EA038691B1 (ru) | 2016-03-28 | 2021-10-05 | Айкор Медикэл Системс, Инк. | Устройство для доставки терапевтических средств |
CN118063563A (zh) | 2016-04-06 | 2024-05-24 | 华盛顿大学 | 用于乙型肝炎病毒(hbv)的使用hbv核心抗原的治疗性疫苗 |
MX2018012376A (es) | 2016-04-13 | 2019-08-01 | Synthetic Genomics Inc | Sistemas de replicón de arterivirus recombinantes y usos de estos. |
KR20190082226A (ko) | 2016-10-17 | 2019-07-09 | 신테틱 제노믹스, 인코포레이티드. | 재조합 바이러스 레플리콘 시스템 및 그의 용도 |
AU2017372731B2 (en) | 2016-12-05 | 2024-05-23 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
GB201705765D0 (en) | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
EP3607968A4 (en) | 2017-06-05 | 2021-03-31 | Beacle Inc. | VIRAL-TYPE PARTICLES INTENDED FOR USE TO INDUCE AN IMMUNE RESPONSE AGAINST HBV |
WO2019099624A1 (en) | 2017-11-16 | 2019-05-23 | University Of Washington | A therapeutic vaccine for hepatitis b virus (hbv) using the hbv pres1 and/or pres2, and/or s-hbsag regions of the hbv envelope protein |
AU2018389786A1 (en) | 2017-12-19 | 2020-06-18 | Bavarian Nordic A/S | Methods and compositions for inducing an immune response against hepatitis B virus (HBV) |
MX2020006478A (es) | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Metodos y aparatos para el suministro de vacunas contra el virus de la hepatitis b (hbv). |
-
2018
- 2018-12-18 US US16/223,400 patent/US11020476B2/en active Active
- 2018-12-18 EA EA202091516A patent/EA202091516A1/ru unknown
-
2021
- 2021-05-18 US US17/323,082 patent/US20210268104A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20190184011A1 (en) | 2019-06-20 |
US20210268104A1 (en) | 2021-09-02 |
US11020476B2 (en) | 2021-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091516A1 (ru) | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) | |
EA201890355A1 (ru) | Новые способы индукции иммунного ответа | |
MX2017002791A (es) | Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante. | |
MX2020006471A (es) | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). | |
PH12018500199A1 (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof | |
DK3584252T3 (da) | Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf | |
MX2015008847A (es) | Composiciones inmunogenicas de virus de influenza y usos de las mismas. | |
NZ729519A (en) | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin | |
EA201890042A1 (ru) | Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) | |
EA201790507A1 (ru) | Способы и композиции для усиления иммунных ответов | |
EA201800148A1 (ru) | Оспенная вакцина для лечения рака | |
EA201890527A1 (ru) | Терапевтические вакцины против hpv18 | |
EA201390866A1 (ru) | Филовирусные вакцины на основе аденовирусов серотипа 26 и серотипа 35 | |
EA201591888A1 (ru) | Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов | |
EA202090149A1 (ru) | Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения | |
EA201891945A2 (ru) | Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv) | |
EA202090049A1 (ru) | Поксвирусные векторы, кодирующие антигены вич, и способы их применения | |
EA201891460A1 (ru) | Композиция дендритных клеток | |
EA201892735A1 (ru) | Состав вакцины против hiv | |
CY1124707T1 (el) | Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων) | |
WO2017132332A8 (en) | Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes | |
EA201591798A1 (ru) | Композиции и способы усиления иммунного ответа на кишечные патогены | |
DK3407910T3 (da) | Rekombinant modificeret vaccinia virus ankara (mva)-vaccine mod hesteencephalitisvirus | |
EA201990711A1 (ru) | Новый ehv сайт инсерции orf70 | |
EA202091104A1 (ru) | Аденовирус и пути его применения |